Epigenetic Nucleosomes in Plasma for Pulmonary Nodule Differentiation

Recruiting now

Conditions studied: Lung Nodule

In brief

Investigators aim to evaluate the diagnostic accuracy of the Nu.Q blood test for lung cancer in the Taiwanese population and compare its diagnostic performance with low-dose computed tomography (LDCT) or computed tomography (CT). Additionally, investigators will investigate the potential role of Nu.Q in lung cancer prevention and its impact on survival outcomes. Study Method: Investigators plan to collect 20 mL of blood samples from individuals undergoing chest LDCT/CT, isolate plasma for Nu.Q™ analysis, and compare the results with corresponding lung cancer pathology findings. The estimated sample size is 500 participants.

Key facts

Study ID

NCT06838806

Run by

National Taiwan University Hospital

People needed

500

Starts

2025-03-11

Expected to finish

2026-03-31

Last updated by the study team

2025-11-19

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged 20 or older
• Underwent a low-dose chest CT scan or a standard chest CT scan, showing lung nodules ≥ 6mm
• Individuals understand the content of the consent form and are willing to participate in this study.
• The lung nodule is assessed by a physician as high-risk, requiring thoracic surgery or biopsy for diagnosis

You may not qualify if…

• Pregnant women
• Individuals without capacity for consent, unable to understand the content of the consent form, or unwilling to participate in this study
• Assessed by a physician as unsuitable for thoracic surgery or biopsy for diagnosis

Where it is running

• National Taiwan University — Taipei, Taiwan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.